ArticleMedicine2026
OCT angiography-derived biomarkers of retinal and choroidal microvascular changes in dry age-related macular degeneration.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optical Coherence Tomography Biomarkers Predicting Progression to Atrophy in Non-Exudative Age-Related Macular Degeneration.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to identify optical coherence tomography angiography (OCTA) biomarkers associated with disease severity in dry age-related macular degeneration (dAMD). This cross-sectional study included 142 eyes (104 patients) with dAMD, classified as early (n = 34), intermediate (n = 40), or late stage (n = 37) according to the Beckman Classification, and 30 control eyes without AMD. OCTA-images were obtained using the ZEISS PLEX Elite 9000, vascular metrics such as vessel density, total number of junctions, total and average vessel length, junction density, total number of endpoints, and lacunarity were assessed in the superficial capillary plexus, deep capillary plexus (DCP), and choriocapillaris (CC) using AngioTool software. The CC showed the most pronounced changes, with vessel percentage area reduced from 58.98 ± 4.86% in controls to 52.14 ± 10.30% in intermediate and 31.34 ± 11.27% in late AMD (P <.001). Total vessel length declined from 407.52 ± 16.33 mm to 367.09 ± 49.18 mm and 217.23 ± 86.88 mm, respectively (P <.001), while lacunarity increased nearly 50-fold in late AMD (0.56 ± 0.91 vs 0.01 ± 0.00; P <.001). In the DCP, vessel percentage area decreased from 45.68 ± 4.92% in controls to 41.95 ± 5.08% in intermediate and 38.24 ± 6.71% in late AMD (P <.001). Vessel length dropped from 275.21 ± 21.82 mm to 254.13 ± 28.78 mm and 224.68 ± 36.37 mm (P <.001), with increased lacunarity in intermediate and late stages (P <.01). The superficial capillary plexus showed early alterations, with vessel percentage area reduced from 41.46 ± 1.58% in controls to 39.42 ± 3.45% in early AMD (P = .017) and total vessel length decreased from 202.85 ± 10.65 mm to 191.42 ± 18.67 mm and 185.92 ± 18.09 mm in intermediate AMD (P <.001). Mean lacunarity was elevated in all AMD stages (P <.001). OCTA reveals distinct, layer-specific microvascular changes in AMD mainly within DCP and CC. Vessel percentage area, total vessel length, and lacunarity represent sensitive, noninvasive OCTA biomarkers of microvascular impairment in dry AMD, with potential applicability for longitudinal disease monitoring and as quantitative imaging endpoints in future interventional trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.